Alexander Lesokhin, MD
Enriched profileAttending Physician; Interim Service Chief, Myeloma Service; Myeloma Specialist & Cellular Therapist · Memorial Sloan Kettering Cancer Center
Alexander Lesokhin is Attending Physician; Interim Service Chief, Myeloma Service; Myeloma Specialist & Cellular Therapist at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 574 publications with 25,437 citations (h-index 59); ClinicalTrials.gov lists 5 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Alexander Lesokhin, M.D., is Attending Physician at Memorial Sloan Kettering Cancer Center. The public record shows 574 publications with 25,437 citations (h-index 59), centered on Multiple Myeloma Research and Treatments, Cancer Immunotherapy and Biomarkers, Monoclonal and Polyclonal Antibodies Research. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 8 companies.
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: Multiple Myeloma Research and Treatments
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 53 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 160.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 16 Oct 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20253 payments
- Genentech USA, Inc.Program year20253 payments
- ABBVIE INC.Program year20256 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
21.8%Thalidomide Analog17.5%Lenalidomide55%Revlimid32%Pomalyst13%Part D≥43 patientsProteasome Inhibitor2.2%Ninlaro100%Part D<11 patients+ 1 more class in this area
Dermatology
21.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor21.3%Acyclovir100%Part D≥71 patientsNervous system
14.6%Opioid Agonist5.6%Oxycodone Hcl40%Fentanyl31%Morphine Sulfate Er29%Part D<11 patientsGabapentinoids5.5%Gabapentin57%Pregabalin43%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 16 Oct 2026
159 congress contributions (2012–2026) across AACR, ASCO, ASH, ENDO per OpenAlex. The most recent:
- A phase 1/2 study of mRNA-2808 in participants with relapsed or refractory multiple myeloma.
ASCO Annual Meeting
ASCO2026Co-author - CAR T-cell detection and clonality assessment in immune effector cell–associated enterocolitis following ciltacabtagene autoleucel.
ASCO Annual Meeting
ASCO2026Co-author - Abstract 996: Dietary patterns in plasma cell disorders: Opportunities for targeted interventions
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma Is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.
Clinical cancer research
Clinical Trial2026 - Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry.
Blood cancer discovery
Article2026 - Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma.
Blood cancer journal
Letter2026 - FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
Nature medicine
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01Nivolumab plus Ipilimumab in Advanced MelanomaArticle4,227 citations2013
- 02PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaArticle3,563 citations2014
- 03Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaArticle2,091 citations2012
- 04
- 05Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 TherapyArticle1,215 citations2016
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/alexander-lesokhin-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/alexander-lesokhin-931795ba
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
healthtree.org/myeloma/community/podcasts/myeloma-immunotherapy-in-review-with-alexander-lesokhin
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Albert Einstein College of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Board certified in Internal Medicine
Medical Oncology, and Hematology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cor2ed.com ↗
Secondary affiliations
appointments beyond the home institution- Member
Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- Podcast: Myeloma Immunotherapy in Review with Alexander Lesokhin
MD (HealthTree Foundation)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens